e.g. mhealth
Search Results (1 to 10 of 15 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 4 JMIR Aging
- 4 JMIR Research Protocols
- 4 JMIRx Med
- 2 JMIR Formative Research
- 1 JMIR Medical Informatics
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Affecting more than 8.5 million people worldwide in 2019, Parkinson disease (PD) is the second most common neurodegenerative disease [1]. PD is diagnosed using criteria from the UK Parkinson’s Disease Society Brain Bank [2] and is defined by the cardinal symptoms of tremor, bradykinesia, rigidity, and postural instability, along with other motor and nonmotor symptoms [3].
JMIR Res Protoc 2025;14:e58612
Download Citation: END BibTex RIS
Neurodegenerative conditions such as Alzheimer disease (AD) and related dementias precipitate accelerated cognitive deterioration, markedly impacting patients’ daily lives and social engagement [1]. Current estimates suggest that approximately 50 million individuals worldwide suffer from dementia, with this number expected to soar to 152 million by 2050 [2]. Generally, patients diagnosed with mild cognitive impairment (MCI) are at a much higher risk of developing dementia [3].
JMIR Med Inform 2025;13:e60250
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Depression affects 280 million people globally and is considered a prodromal feature for increasingly prevalent neurodegenerative conditions, including Parkinson disease (PD). More than 10 million people live with PD, the fastest growing neurological disorder worldwide [1]. Most commonly reported PD symptoms pertain to motor and nonmotor symptoms (NMSs), such as anxiety, depression, fatigue, apathy, cognitive disturbances, and dementia [2-4], significantly impacting health and quality of life (Qo L).
JMIRx Med 2024;5:e44426
Download Citation: END BibTex RIS
Markerless Motion Capture to Quantify Functional Performance in Neurodegeneration: Systematic Review
MMC is attractive for health care and research use, such as monitoring functional performance loss or improvement in neurodegenerative diseases. While traditional movement analyses are based on subjective clinical assessments, MMC can be used to generate objective and quantifiable digital biomarkers that can help detect a decline in functional performance by capturing movement unobtrusively [9]. Variations in these digital biomarkers could indicate underlying impairment and enable earlier support.
JMIR Aging 2024;7:e52582
Download Citation: END BibTex RIS
Frontotemporal lobar degeneration (FTLD) is a common cause of dementia in individuals aged
However, current assessment practices for detecting neurobehavioral changes associated with neurodegenerative disease are limited.
JMIR Aging 2024;7:e52831
Download Citation: END BibTex RIS
Parkinson disease (PD) is the second most common neurodegenerative disease after Alzheimer disease [1]. It is associated with disability, loss of independence, caregiver burden, and premature death [2]. Life expectancy is reduced for all patients, especially in individuals with early-onset PD [2]. More than 75% have dementia after 8 years from diagnosis [3]. PD onset age is typically 60-65 years [4], with early onset being considered between 21 and 50 years [5].
JMIR Form Res 2024;8:e51977
Download Citation: END BibTex RIS
The aging of the population, accompanied by an increase in chronic diseases, including cardiovascular diseases, diabetes, asthma, mental and physical disorders, and neurodegenerative conditions, represents the main cause of this situation [2,3]. In fact, the existence of comorbidities and the confluence of several chronic diseases are progressively more frequent in older adults, which increases the need to develop models and tools to improve integrated health care systems.
JMIR Res Protoc 2023;12:e47916
Download Citation: END BibTex RIS